Company Case Study I The use of a novel dual pro-and post-biotic in adults with IBS D: Results from a multicentre randomized placebo-controlled trial

Increasingly, pre-clinical and clinical research supports the importance of gut health in a wide variety of physiological systems, ranging from digestive health and immune function support to cardiovascular and mental health.

ADM’s most recent clinical study uses the duo pro- and post- biotic Bifidobacterium longum ES1 in a population of adults with IBS-D (irritable bowel syndrome). With nearly 80 % of consumers recognizing the link between digestive health and overall wellbeing (FMCG), it is not surprising this category is the largest amongst biotic products.

Dr. Richard Day, VP Medical Affairs at ADM, will walk us through main findings from this recent clinical study and the science around digestive health and postbiotics. Highlights:

• Explore the use of postbiotics for digestive health
• Review latest clinical trial data from a large multicentre RCT
• First human clinical data for this dual pro- and post-biotic